



**Notice of 2026 Annual General Meeting
(Summarized Translation)**

1. The 2026 Annual General Meeting of Medigen Biotechnology Corp. will be convened at 9:00 a.m. May 26, 2026 (Tuesday). The meeting venue is at 2F, Building A, No. 19-10, Sanchong Road, Nangang District, Taipei City (International Convention Center). Shareholder registration of the meeting starts at 8:30 a.m. and the reception desk is the same as the meeting venue. Meeting agenda:
 - (I) Management Presentations: 1. 2025 Business Report; 2. 2025 Audit Committee's Review Report; 3. 2025 Report on Director Remuneration.
 - (II) Proposals: 1. 2025 Business Report and Financial Statements; 2. 2025 Deficit Compensation .
 - (III) Motions.
2. Where there is any matter that related to Article 172 of the Company Act in the main contents of the annual shareholders' meeting, shareholders may find the details from Market Observation Post System (MOPS) (<https://mops.twse.com.tw>), click on Basic Information/Electronic Books/Annual Report and Shareholders' Meetings, and enter the Company's stock code and year; then, select related information of shareholders' meetings.
3. In accordance with Article 165 of the Company Act, share transfers shall be discontinued during the period starting from March 28, 2026 until May 26, 2026.
4. In addition to the public announcement, a set of Attendance Card and Proxy Form for this shareholders' meeting is hereby attached to this notice. Your presence will be greatly appreciated. If you intend to attend this meeting in person, please fill out the Attendance Card on the second page, sign or stamp it, and hand it directly at the meeting venue on the day of the meeting without the need to return the card in mail. If you entrust a proxy to attend this meeting, please fill out the Proxy Form on the second page, sign or stamp it, and deliver it to the Company's stock affairs agent, Capital Securities Corp., Stock Affairs Department, by mail at least five days before the meeting. The agent will then prepare the Attendance Card and forward it to your designated proxy for use at the meeting.
5. If there is any solicitation of proxy forms, the Company will compile a summary statement of solicitors and disclose it on the website of the Securities and Futures Institute (SFI) by April 24, 2026. Investors may visit the SFI's website at <https://free.sfi.org.tw>, go to the "Free Proxy Information Search" section, and enter the required search criteria to obtain relevant information.



基亞生物科技股份有限公司
MEDIGEN BIOTECHNOLOGY CORP.

6. Shareholders may exercise their voting rights electronically for this shareholders' meeting. The electronic voting period is from April 25, 2026, to May 23, 2026. Please log in to the Taiwan Depository & Clearing Corporation's "Stockvote" website [<https://stockservices.tdcc.com.tw>] and follow the instructions provided to cast your vote.
7. The registrar department of Capital Securities Corporation was appointed as the agent to compile related statistics and verification regarding the proxy for the 2026 Annual General Shareholders' Meeting.

To All Shareholders

MEDIGEN BIOTECHNOLOGY CORP.